Alpine Immune Sciences Inc (ALPN)
64.60
+0.01
(+0.02%)
USD |
NASDAQ |
May 03, 16:00
64.60
0.00 (0.00%)
After-Hours: 18:45
Alpine Immune Sciences Cash from Financing (Quarterly): 156.61M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 156.61M |
| September 30, 2023 | 1.201M |
| June 30, 2023 | 8.398M |
| March 31, 2023 | -1.087M |
| December 31, 2022 | 11.54M |
| September 30, 2022 | 92.82M |
| June 30, 2022 | -1.02M |
| March 31, 2022 | -0.65M |
| December 31, 2021 | 10.87M |
| September 30, 2021 | 89.68M |
| June 30, 2021 | 0.009M |
| March 31, 2021 | 0.202M |
| December 31, 2020 | -0.011M |
| September 30, 2020 | 56.39M |
| June 30, 2020 | 0.002M |
| March 31, 2020 | 5.00M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 1.646M |
| June 30, 2019 | -0.509M |
| March 31, 2019 | 23.12M |
| Date | Value |
|---|---|
| December 31, 2018 | -0.50M |
| September 30, 2018 | -0.498M |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.007M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 42.69M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.063M |
| September 30, 2016 | 0.011M |
| June 30, 2016 | 0.092M |
| March 31, 2016 | |
| December 31, 2015 | 0.062M |
| September 30, 2015 | -2.104M |
| June 30, 2015 | 80.88M |
| March 31, 2015 | |
| December 31, 2014 | 29.89M |
| September 30, 2014 | 4.088M |
| June 30, 2014 | 2.603M |
| March 31, 2014 | 4.582M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.087M
Minimum
Mar 2023
156.61M
Maximum
Dec 2023
22.69M
Average
1.201M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | -119.80M |
| Eliem Therapeutics Inc | 0.288M |
| Regeneron Pharmaceuticals Inc | -446.10M |
| Vera Therapeutics Inc | 24.83M |
| Eyenovia Inc | 0.6143M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.97M |
| Cash from Investing (Quarterly) | -112.70M |
| Free Cash Flow | -79.50M |
| Free Cash Flow Per Share (Quarterly) | -0.3461 |
| Free Cash Flow to Equity (Quarterly) | -19.08M |
| Free Cash Flow to Firm (Quarterly) | -19.08M |
| Free Cash Flow Yield | -2.46% |